Unaudited Financial Results for the half year ended on 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts more than Nifty Microcap 250 and 5.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aptus Pharma reported strong H1 FY26 results with total revenue of Rs. 1,437.75 lakhs, up 47.38% year-on-year from Rs. 975.57 lakhs. EBITDA grew 36.12% to Rs. 294.55 lakhs, though margin contracted by 169 basis points to 20.49%. Profit after tax rose 33.81% to Rs. 174.69 lakhs, with PAT margin at 12.15%. The company utilized its full IPO proceeds of Rs. 1,302 lakhs towards capital expenditure, working capital, and issue expenses. The statutory auditor ABKB & Co. issued an unqualified limited review report with no qualifications. Cash and bank balances jumped sharply to Rs. 1,428 lakhs on the back of fresh equity infusion, but operating cash flow was negative at Rs. (92.14) lakhs, and trade receivables rose sharply to Rs. 1,007 lakhs from Rs. 564 lakhs.
Strong top-line and profit growth are positives for shareholders, but margin compression and negative operating cash flow suggest rising working capital pressure. The sharp jump in receivables and reliance on IPO funds for working capital indicate the company may need to monitor cash conversion closely despite headline growth.